Safety of Continuous Nebulized Albuterol for Bronchospasm in Infants and Children

Objective. To determine the incidence of cardiotoxicity in infants and children who receive continuous nebulized albuterol (CNA) for bronchospasm. Design. Frospective, case series. Setting. A university pediatric intensive care and pediatric subacute units. Patients. Nineteen infants and children who received CNA for at least 24 hours. Interventions. None. Measuremnts. Creatinine phosphokinase (CK) was measured at the time of admission and then at 12, 24, 48, and 72 hours while the patient received CNA. Isoenzyme CK-MB fractions were measured if CK concentration was ≥250 IU/L. One electrocardiogram was obtained for each patient during CNA treatment. All patients had continuous cardiac monitoring during continuous nebulization therapy